Earle A. Chiles Research Institute

New trial open at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, is enrolling patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.

Final outcomes from a Providence Cancer Institute-sponsored phase Ib trial evaluating pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic TNBC.

Researchers from Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, shared their investigations to advance cancer research and treatments at the premier event.

New investigator-initiated trial at Providence to evaluate a triple combination of medications for treating melanoma, and two new studies evaluating medication combinations to treat AML.

Providence researchers awarded an R21 grant from the National Institutes of Health which provides funding for projects with potential to significantly advance biomedical research.

Studies open at Providence Cancer Institute in Oregon for patients with head and neck cancer and patients with breast cancer that has metastasized in the brain.

New trials available at Earle A. Chiles Research Institute for patients with human epidermal growth factor receptor 2 positive (HER2+) colorectal cancer and patients with cholangiocarcinoma.

A new trial offered at Providence Cancer Institute is enrolling patients with early-stage HR-positive and HER2-negative breast cancer.

As part of an international data-sharing consortium of leading cancer centers, Providence Cancer Institute and Swedish Cancer Institute work together to provide genomic data to Project GENIE.

Using MRI-guided radiation, Providence radiation oncologists can precisely target tumors for destruction while minimizing damage to surrounding normal tissue.

A new clinical trial offered at Providence Cancer Institute to study the safety and effectiveness of two different treatments for people under age 70 with previously untreated non-GCB DLBCL.

Providence Cancer Institute is offering a phase III trial for patients with gynecologic cancers and two early phase trials that will study new medications in treating solid tumors.

Providence currently accepting applications for an Immuno-Oncology Research Fellowship being offered through Earle A. Chiles Research Institute.

Bernard A. Fox, Ph.D., leader of the Laboratory of Molecular and Tumor Immunology honored by the Society for Immunotherapy of Cancer for legacy of public service.

Providence Cancer Institute one of only a few sites worldwide offering two new clinical trials for solid tumors and lung cancer.

Providence Cancer Institute is currently recruiting participants for three new clinical studies offered for people with HER2-neu negative breast cancer.

New investigator-initiated clinical trial available only at Providence Cancer Institute will evaluate the safety and efficacy of targeted therapy combination for treating thyroid cancer.